People In the News: Amicus, Catabasis, Astellas Add Reg/Policy Execs

Andrew Mulberg leaves US FDA for Amicus Therapeutics. Ipsen, Iroko, TapImmune make topside changes.

David Meek takes the helm at Ipsen July 18 as its new CEO. He had headed oncology programs at Baxalta Inc., now part of Shire PLC following the June close of its acquisition.

Iroko Pharmaceuticals LLC President Louis Vollmer adds the CEO title. Company founder and outgoing CEO Osagie Imasogie remains as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

Global Pharma Guidance Tracker - June 2025

 

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

US FDA’s CRL Release More Incremental Than ‘Radical’ Transparency

 

The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.